新たに診断された小児1型糖尿病における臓ベータ細胞機能に対する厳密な血糖制御の効果: ランダム化臨床試験
Jennifer McVean1,2, Gregory P Forlenza3, Roy W Beck4
1University of Minnesota, Minneapolis.
JAMA
|February 24, 2023
まとめ
新型糖尿病の若者における自動インスリン投与による糖尿病の集中治療は,血糖のコントロールを改善したが,臓のβ細胞機能を保たなかった. この発見は1型糖尿病におけるベータ細胞機能の保存に関するさらなる研究の必要性を強調しています.
科学分野:
- 内分泌学
- 代謝 疾患
- 小児 糖尿病 研究
背景:
- 1型糖尿病 (T1D) の治療は,グルコ毒性を予防し,臓のβ細胞機能を維持することを目的としています.
- 以前の研究では,ベータ細胞の保存のための厳格な血糖制御を達成することに問題がありました.
- 新たに診断されたT1Dのグルコース毒性を減らすための潜在的な戦略です.
研究 の 目的:
- 新たに診断されたT1Dの若者における臓β細胞機能の保存における糖尿病の集中管理の有効性を評価する.
- 自動インスリン投与システムがグルコースレベルをほぼ正常化させ,ベータ細胞機能に影響を与えるかどうかを判断する.
- 小児T1DにおけるCペプチド分泌に対する濃縮血糖制御の長期的効果を評価する.
主な方法:
- 新しいT1Dの診断を受けた113人の若者 (7歳から17歳) を対象としたランダム化,ダブルブラインド臨床試験.
- 参加者は,自動インスリン投与システムによる糖尿病の集中治療か,継続的な血糖モニターによる標準治療のいずれかに割り当てられました.
- 測定された主なアウトカムは,Cペプチドの曲線下の領域の変化 (AUC) で,52週間の混合食事耐性試験でした.
主要な成果:
- 集中治療群は52週間の標準治療 (64%) と比較して,より長い期間 (78%) を達成した.
- 集中治療群と標準治療群の間で,CペプチドAUCの減少において有意な差は認められなかった (P=0. 89).
- 両グループは重度の低血糖症と糖尿病性ケトアシドーシスの割合が類似した.
結論:
- 自動インスリン投与を含む糖尿病の集中管理は,新たにT1Dと診断された若者の血糖コントロールを効果的に改善します.
- この集中的なアプローチは,52週後に臓のベータ細胞機能 (Cペプチド分泌) の維持に有意な効果を示さなかった.
- 小児のT1Dでは,優れた血糖制御を達成する以外に,ベータ細胞機能を保護するためのさらなる戦略が必要である.
さらに関連する動画
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Carbohydrate Metabolism
11.3K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Diabetes: Management and Pharmacotherapy
324
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
324
Insulin: Dosing Regimen and Adverse Effects
223
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
223


